GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Forward PE Ratio

Eledon Pharmaceuticals (FRA:2TK) Forward PE Ratio : 0.00 (As of Jun. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Forward PE Ratio?

Eledon Pharmaceuticals's Forward PE Ratio for today is 0.00.

Eledon Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Eledon Pharmaceuticals's PE Ratio for today is 0.00.


Eledon Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Eledon Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Forward PE Ratio Chart

Eledon Pharmaceuticals Annual Data
Trend 2021-09 2022-12
Forward PE Ratio
5.21 2.11

Eledon Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Eledon Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Eledon Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Forward PE Ratio falls into.



Eledon Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Eledon Pharmaceuticals  (FRA:2TK) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Eledon Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals (FRA:2TK) Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines